Publications by authors named "J A Suaya"
Article Synopsis
- - In 2014, the PCV13 vaccine was recommended for adults 65 and older, aiming to reduce invasive pneumococcal disease (IPD), yet cases of serotype 3 lingered despite overall declines in other serotypes.
- - A study conducted from 2014 to 2020 within Kaiser Permanente Northern California evaluated the effectiveness of PCV13 in preventing IPD in this age group, analyzing over 610,000 participants.
- - The findings showed that the vaccine was 61.5% effective against PCV13-serotype IPD and 46.3% effective against serotype 3, highlighting the need for ongoing monitoring of vaccine impact on IPD across different serotypes. *
Objectives: Pneumonia hospitalization studies using administrative claims rely on pneumonia coded in the first discharge diagnosis field over pneumonia in any coded field, and few have evaluated disposition following discharge. This study reports the total disease burden and discharge disposition among patients with pneumonia coded in any diagnosis field.
Study Design: Retrospective database review.
Background: Vaccine regulatory decision making is based on vaccine efficacy against etiologically confirmed outcomes, which may underestimate the preventable disease burden. To quantify this underestimation, we compared vaccine-preventable disease incidence (VPDI) of clinically defined outcomes with radiologically/etiologically confirmed outcomes.
Methods: We performed a systematic review of efficacy trials for several vaccines (1997-2019) and report results for pneumococcal conjugate vaccines.
Background: In 2010-2011, the 13-valent pneumococcal conjugate vaccine (PCV13) replaced the 7- or 10-valent vaccine (PCV7 and PCV10, respectively) in pediatric immunization programs across Canada. For adults aged ≥65 years, the 23-valent pneumococcal polysaccharide vaccine (PPSV23) has been publicly funded for several decades; PCV13 funding was not recommended in this population, partly due to expected ongoing vaccine-serotype disease decline stemming from herd effects of the pediatric program. Higher-valent PCVs (ie, 15- and 20-valent PCVs [PCV15 and PCV20, respectively]) currently in development may become available in Canada in the coming years.
View Article and Find Full Text PDFHospital-acquired pneumonia (HAP) is often more severe and life-threatening than community-acquired pneumonia (CAP). The role of Streptococcus pneumoniae in CAP is well-understood, but its role in HAP is unclear. The objective of this study was to summarize the available literature on the prevalence of S.
View Article and Find Full Text PDF